LWLaura Fink Wayerbacher

Laura Fink Wayerbacher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Fink Wayerbacher has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes across the Spectrum of Kidney Disease

    by Bernardo F. Spiazzi, Giovana F. Piccoli, Laura F. Wayerbacher, João Pedro N. Lubianca, Bruno G. Scalco, Mariana H. Scheffler, Bruna L. Fraga, Verônica Colpani, Fernando Gerchman

    Key Points: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk. Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remains uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease Improving Global Outcomes (KDIGO) classification and urinary albumin-creatinine ratio (UACR) levels. Methods: We have searched medical literature analysis and retrieval system online (PubMed), excerpta medica database, and Cochrane Central Register of Controlled Trials from inception up to August 8, 2023. In pairs, researchers selected large (≥500 participants per arm) randomized placebo-controlled trials of SGLT2 inhibitors, with a minimum duration of 1 year. Researchers independently extracted study-level data and assessed within-study risk of bias with the risk of bias 2.0 tool and quality of evidence with grading of recommendations, assessment, development and evaluation. Results: We included ten trials, encompassing 78,184 participants and a median follow-up of 2.7 years. Risk of bias was overall low. We performed meta-analyses summarizing individual study hazard ratios (HRs) and 95% confidence intervals (CIs) using a random-effects model. SGLT2 inhibitors reduced the composite kidney outcome across all KDIGO (HR [95% CI]: low 0.48 [0.32 to 0.71], moderate 0.60 [0.39 to 0.93], high 0.59 [0.47 to 0.74], very high 0.59 [0.49 to 0.72]) and UACR (HR [95% CI]: 300 mg/g 0.61 [0.52 to 0.73]) groups, without evidence of heterogeneity between groups. A small proportion of participants without diabetes in low-risk groups were referred, and there was lack of standardization of composite outcomes. Conclusions: SGLT2 inhibitors consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels. Clinical Trial registry name and registration number: CRD42023492877.


  • “What really matters to the patients?”: assessing the impact of wound healing on the quality of life in patients undergoing incisional hernia repair

    by Eduardo Ferreira Martins, Rodrigo Piltcher -Da -Silva, Lara Luz de Miranda Silva, Pedro San Martin Soares, Marcos Dal Vesco Neto, Lucas dos Santos Difante, Isadora Bosini Remus, Laura Fink Wayerbacher, Victoria de Jorge, Bernardo Silveira Volkweis, et al.

    Purpose We aim to evaluate the impact of surgical wound complications in the first 30 postoperative days after incisional hernia repair on the long-term quality of life of patients. In addition, the impact of the surgical technique and preoperative comorbidities on the quality of life of patients will also be evaluated. Method Prospective cohort study, which evaluates 115 patients who underwent incisional hernioplasty between 2019 and 2020, using the onlay and retromuscular techniques. These patients were initially assessed with regard to surgical wound outcomes in the first 30 postoperative days (surgical site infection (SSI) or surgical site occurrence (SSO)), and then, assessed after three years, through a specific quality of life questionnaire, the Hernia Related Quality of Life Survey (HerQLes). Results After some patients were lost to follow-up during the study period, due to death, difficulty in contact, refusal to respond to the questionnaire, eighty patients were evaluated. Of these, 11 patients (13.8%) had SSI in the first 30 postoperative days and 37 (46.3%) had some type of SSO. The impact of both SSI and SSO on quality of life indices was not identified. When analyzing others variables, we observed that the Body Mass Index (BMI) had a significant impact on the patients’ quality of life. Likewise, hernia size and mesh size were identified as variables related to a worse quality of life outcome. No difference was observed regarding the surgical techniques used. Conclusion In the present study, no relationship was identified between surgical wound outcomes (SSO and SSI) and worse quality of life results using the HerQLes score. We observed that both BMI and the size of meshes and hernias showed an inversely proportional relationship with quality of life indices. However, more studies evaluating preoperative quality of life indices and comparing them with postoperative indices should be carried out to evaluate these correlations.


  • Validation of the carolinas comfort scale (CCS) in Brazil: a hernia-specific quality of life questionnaire

    by Rodrigo Piltcher-Da-Silva, Pedro San Martin Soares, Eduardo Ferreira Martins, Laura Fink Wayerbacher, Leandro Totti Cavazzola

    Introduction Ventral hernia surgery (VHS) has the intent to promote a better quality of life (QoL). VHS results were evaluated by recurrence incidence in the past, however the concept of Patient-Reported Outcomes Measures has changed this scenario. SF-36 is a generic questionnaire with some limitations on the hernioplasty postoperative evaluation. Disease-specific surveys such Hernia-Related Quality of Life Survey (HerQLes) and Carolinas Comfort Scale (CCS) were developed to improve specificity. The aim of this study was to validate a Brazilian version of the CCS as a QoL questionnaire for patients undergoing VHS in Brazil. Materials and methods The study consists of a retrospective cohort that reviewed the medical records of patients who underwent ventral hernia surgery for incisional hernias in the Hospital de Clínicas de Porto Alegre between January 2019 to December 2020. Participants answered both the HerQles questionnaire and the CCS, then we compared the patients’ scores between scales. In-personal evaluations or surveys applied by telemedicine were performed. Intraclass correlation coefficient was utilized to assess the consistency of the agreement between the HerQLes and CCS scales. Results A sample of 80 patients were evaluated. Most were male (70%), mean age 61.11 years and BMI 28.4. The most common comorbidity was systemic arterial hypertension, one third were smokers and 77.5% of cases were ASA 2. The average HerQLes score was 30.40 and the CCS was 15.46 (SD: 21.81), with an intraclass coefficient of 0.68. Conclusion This study suggests that CCS is a good and robust tool for assessing ventral hernia. Tools to measure QoL are increasingly used in the literature, as QoL seems to be important data to assess surgical success, since it shows the perception of the patient about the results of their surgery. Further studies with larger sample sizes should be performed to confirm our findings.


  • Long-term lifestyle intervention can reduce the development of type 2 diabetes mellitus in subjects with prediabetes: A systematic review and meta-analysis

    by Paula Portal Teixeira, Kelly Pozzer Zucatti, Lucas Strassburger Matzenbacher, Laura Fink Wayerbacher, Minghui Zhang, Verônica Colpani, Fernando Gerchman


  • Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis

    by Leonardo A. Mesquita, Bernardo F. Spiazzi, Giovana F. Piccoli, Daniela A. Nogara, Gabriella R. da Natividade, Henrique I. Garbin, Laura F. Wayerbacher, Vanessa M. Wiercinski, Viviane A. Baggio, Carolina P. Zingano, et al.

    Aim: To evaluate the effect of metformin on cancer incidence in subjects with overweight/obesity and/or prediabetes/diabetes. Materials and Methods: We searched MEDLINE, Embase and CENTRAL for randomized controlled trials (RCTs) in adults with overweight/obesity and/or prediabetes/diabetes that compared metformin to other interventions for ≥24 weeks. Independent reviewers selected and extracted data including population and intervention characteristics and new diagnoses of cancer. We used the RoB 2.0 risk‐of‐bias tool and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework to assess risk of bias and certainty of evidence. Results: From 14 895 records after removal of duplicates, 27 trials were included, providing a total of 10 717 subjects in the metformin group and 10 003 in the control group, with 170 and 208 new cases of cancer, respectively. Using a random‐effects model, the relative risk was 1.07 (95% confidence interval 0.87–1.31), with similar results in subgroup analyses by study duration or effect of control intervention on weight. Risk of bias in most studies was low, and no evidence of publication bias was found. Trial sequential analysis provided evidence that the cumulative sample size was large enough to exclude a significant effect of metformin on cancer incidence. Conclusions: Metformin did not reduce cancer incidence in RCTs involving subjects with overweight/obesity and/or prediabetes/diabetes.


  • Open Access

    Coconut oil: an overview of cardiometabolic effects and the public health burden of misinformation

    by Bernardo Frison Spiazzi, Ana Cláudia Duarte, Carolina Pires Zingano, Paula Portal Teixeira, Carmen Raya Amazarray, Eduarda Nunes Merello, Laura Fink Wayerbacher, Laura Penso Farenzena, Poliana Espíndola Correia, Marcello Casaccia Bertoluci, et al.

    Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in [...] ABSTRACT Recent data from meta-analyses of randomized clinical trials (RCTs) suggest that dietary intake of coconut oil, rich in saturated fatty acids, does not result in cardiometabolic benefits, nor in improvements in anthropometric, lipid, glycemic, and subclinical inflammation parameters. Nevertheless, its consumption has surged in recent years all over the world, a phenomenon which can possibly be explained by an increasing belief among health professionals that this oil is as healthy as, or perhaps even healthier than, other oils, in


  • Open Access

    Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions

    by Leonardo de Andrade Mesquita, Laura Fink Wayerbacher, Gilberto Schwartsmann, Fernando Gerchman

    The proportion of deaths attributable to cancer is rising, and malignant neoplasms have become the leading cause of death in high-income countries. Obesity and diabetes are now recognized as risk factors for several types of malignancies, especially endometrial, colorectal, and postmenopausal breast cancers. Mechanisms implicated include disturbances in lipid-derived hormone secretion, sex steroids biosynthesis, hyperinsulinemia, and chronic inflammation. Intentional weight loss is associated with a mitigation of risk for obesity-related cancers, a phenomenon observed specially with bariatric surgery. The [...] ABSTRACT The proportion of deaths attributable to cancer is rising, and malignant neoplasms have become the leading cause of death in high-income countries. Obesity and diabetes are now recognized as risk factors for several types of malignancies, especially endometrial, colorectal, and postmenopausal breast cancers. Mechanisms implicated include disturbances in lipid-derived hormone secretion, sex steroids biosynthesis, hyperinsulinemia, and chronic inflammation. Intentional weight loss is associated with a mitigation of risk for obesity-related cancers, a phenomenon observed specially with bariatric surgery. The


  • Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials

    by Bernardo F. Spiazzi, Rafaella A. Naibo, Laura F. Wayerbacher, Giovana F. Piccoli, Laura P. Farenzena, Thizá M. Londero, Gabriella R. da Natividade, Maira Zoldan, Nathália A.H. Degobi, Matheus Niches, et al.